You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Baxter
Medtronic
McKesson
Colorcon

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for IMO-2125

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for IMO-2125?

IMO-2125 is an investigational drug.

There have been 18 clinical trials for IMO-2125. The most recent clinical trial was a Phase 2 trial, which was initiated on February 28th 2018.

The most common disease conditions in clinical trials are Melanoma, Hepatitis C, and Psoriasis. The leading clinical trial sponsors are Idera Pharmaceuticals, Inc., EMD Serono, and A.J.M. van den Eertwegh.

There are three US patents protecting this investigational drug and nine international patents.

Recent Clinical Trials for IMO-2125
TitleSponsorPhase
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 MelanomaIdera Pharmaceuticals, Inc.Phase 2
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 MelanomaA.J.M. van den EertweghPhase 2
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Idera Pharmaceuticals, Inc.Phase 2

See all IMO-2125 clinical trials

Clinical Trial Summary for IMO-2125

Top disease conditions for IMO-2125
Top clinical trial sponsors for IMO-2125

See all IMO-2125 clinical trials

US Patents for IMO-2125

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IMO-2125   Start Trial Immune modulation with TLR9 agonists for cancer treatment IDERA PHARMACEUTICALS, INC. (Exton, PA)   Start Trial
IMO-2125   Start Trial Immune modulation with TLR9 agonists for cancer treatment IDERA PHARMACEUTICALS, INC. (Exton, PA)   Start Trial
IMO-2125   Start Trial Immune modulation with TLR9 agonists for cancer treatment IDERA PHARMACEUTICALS, INC. (Exton, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IMO-2125

Drugname Country Document Number Estimated Expiration Related US Patent
IMO-2125 Australia AU2017325981 2036-09-15   Start Trial
IMO-2125 Canada CA3036978 2036-09-15   Start Trial
IMO-2125 China CN110114057 2036-09-15   Start Trial
IMO-2125 European Patent Office EP3512499 2036-09-15   Start Trial
IMO-2125 Israel IL265370 2036-09-15   Start Trial
IMO-2125 Japan JP2019529415 2036-09-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Baxter
Medtronic
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.